FDA Issues Form 483 to Zhejiang Hisun Pharmaceuticals [8.11.17 483]
FDA Issues Form 483 to Zhejiang Hisun Pharmaceuticals
TAIZHOU, China, June 30, 2020 /PRNewswire/ -- Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.
TAIZHOU, China, June 26, 2020 /PRNewswire/ -- Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.
TAIZHOU, China, June 26, 2020 /PRNewswire/ -- Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.
TAIZHOU, Chine--(BUSINESS WIRE)--Ce document a été envoyé de la ville de Taizhou, dans la province du Zhejiang, le 26 juin 2020. Le Favipiravir est un inhibiteur antiviral large spectre de la RdRp appourvé pour divers virus comme la grippe, le coronavirus et Ebola, et aucun effet indésirable évident n’a été signalé depuis sa mise sur marché. Contrairement aux médicaments antiviraux généraux, le Favipiravir bloque directement la réplication du virus dans les cellules, son mécanisme d’action est similaire à celui du Remdesivir.
TAIZHOU, China--(BUSINESS WIRE)--Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.
Zhejiang Hisun Pharmaceutical on Health Canada Inspection list
Since the outbreak of COVID-19, people around the globe have been eagerly awaiting a real breakthrough on its treatment. Fortunately, a silver lining seems finally to be showing up.
ince the outbreak of COVID-19, people around the globe have been eagerly awaiting a real breakthrough on its treatment. Fortunately, a silver lining seems finally to be showing up.